88056 Federal Register / Vol. 89, No. 215 / Wednesday, November 6, 2024 / Notices 

AIDS (PACHA or the Council) will 

convene the 83rd full council meeting 

on Wednesday, December 11–Thursday, 

December 12, 2024 at the DoubleTree 

Hotel in Montgomery, Alabama. The 

meeting will include panels on the 

history of the civil rights movement in 

the South and how it impacts HIV 

disparities today, the intersection of 

HIV, stigma, and social determinants of 

health, the epidemiology of HIV in 

Alabama and local solutions for 

advancing health justice and addressing 

HIV disparities. The meeting will also 

include subcommittee updates and a 

‘‘PACHA-to-the-People’’ community 

engagement session. The meeting will 

be open to the public and there will be 

a public comment session during the 

meeting; pre-registration is required to 

provide public comment. To pre-register 

to provide public comment, please send 

an email to PACHA@hhs.gov and 

include your name, organization, and 

title by close of business Wednesday, 

December 4, 2024. If you decide you 

would like to provide public comment 

but do not pre-register, you may submit 

your written statement by emailing 

PACHA@hhs.gov by close of business 

Thursday, December 19, 2024. The 

meeting agenda will be posted on the 

PACHA page on HIV.gov at https://

www.hiv.gov/federal-response/pacha/ 

about-pacha prior to the meeting. 

DATES: The meeting will convene on 

Wednesday, December 11, 2024 from 

approximately 3 p.m. to 7 p.m. (ET) and 

Thursday, December 12, 2024 from 

approximately 10 a.m. to 6 p.m. (ET). 

ADDRESSES: DoubleTree Hotel at 120 

Madison Avenue, Montgomery, 

Alabama 36104. To stream the meeting, 

please visit www.hhs.gov/live. 

FOR FURTHER INFORMATION CONTACT: Ms. 

Chloe Loving, MPH, Committee 

Manager for PACHA, at PACHA@

hhs.gov or 202–795–7697. Additional 

information can be obtained by 

accessing the Council’s page on the 

HIV.gov site at www.hiv.gov/pacha. 

SUPPLEMENTARY INFORMATION: PACHA 

was established by Executive Order 

12963, dated June 14, 1995, as amended 

by Executive Order 13009, dated June 

14, 1996 and is currently operating 

under the authority given in Executive 

Order 14109, dated September 29, 2023. 

The Council was established to provide 

advice, information, and 

recommendations to the Secretary 

regarding programs and policies 

intended to promote effective HIV 

diagnosis, treatment, prevention, and 

quality care services. The functions of 

the Council are solely advisory in 

nature. 

The Council consists of not more than 

35 members. Council members are 

selected from prominent community 

leaders with particular expertise in, or 

knowledge of, matters concerning HIV 

and AIDS, public health, global health, 

population health, philanthropy, 

marketing or business, as well as other 

national leaders held in high esteem 

from other sectors of society. PACHA 

selections also include persons with 

lived HIV experience and persons 

disproportionately affected by HIV. 

Council members are appointed by the 

Secretary. 

Dated: October 29, 2024. 

Caroline Talev, 

Executive Director, Presidential Advisory 

Council on HIV/AIDS, Senior Management 

Analyst, Office of Infectious Disease and HIV/ 

AIDS Policy, Office of the Assistant Secretary 

for Health, Department of Health and Human 

Services. 

[FR Doc. 2024–25818 Filed 11–5–24; 8:45 am] 

BILLING CODE 4150–43–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Research Initiative for 

Vaccine and Antibiotic Allergy (UG3/UH3 

Clinical Trial Not Allowed). 

Date: December 5, 2024. 

Time: 12:00 p.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G56, 

Rockville, MD 20892 (Video Assisted 

Meeting). 

Contact Person: Poonam Tewary, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3G56, Rockville, MD 

20892, (240) 669–5047, (301) 761–7219, 

tewaryp@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: October 31, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–25750 Filed 11–5–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Complementary & 

Integrative Health; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Center for 

Complementary and Integrative Health 

Special Emphasis Panel; REsearch Across 

Complementary and Integrative Health 

Institutions (REACH) Virtual Resource 

Centers (U24 Clinical Trial Not Allowed). 

Date: December 3, 2024. 

Time: 11:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Center for 

Complementary and Integrative Democracy 

II, 6707 Democracy Blvd., Bethesda, MD 

20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Marta V. Hamity, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review, Division of Extramural Activities, 

NCCIH/NIH, 6707 Democracy Boulevard, 

Suite 401, Bethesda, MD 20892, 

marta.hamity@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.213, Research and Training 

in Complementary and Alternative Medicine, 

National Institutes of Health, HHS). 


khammond on DSKJM1Z7X2PROD with NOTICES